BMPR-IA/ALK-3 Products
Cellular responses to bone morphogenetic proteins (BMPs) are mediated by the formation of hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors. There are seven known type I serine/threonine kinases and five mammalian type II serine/threonine kinase receptors that function in TGF-beta superfamily signal transduction. The type II receptors for TGF-beta and activin bind ligands with high affinity by themselves. In contrast, BMPR-II binding to BMP-2, BMP-4, and BMP-7 is facilitated by the presence of the type I receptor. The type I receptors are also known as activin receptor-like kinases or ALKs.
87 results for "BMPR-IA/ALK-3" in Products
87 results for "BMPR-IA/ALK-3" in Products
BMPR-IA/ALK-3 Products
Cellular responses to bone morphogenetic proteins (BMPs) are mediated by the formation of hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors. There are seven known type I serine/threonine kinases and five mammalian type II serine/threonine kinase receptors that function in TGF-beta superfamily signal transduction. The type II receptors for TGF-beta and activin bind ligands with high affinity by themselves. In contrast, BMPR-II binding to BMP-2, BMP-4, and BMP-7 is facilitated by the presence of the type I receptor. The type I receptors are also known as activin receptor-like kinases or ALKs.
Potent and selective ALK2 and ALK3 inhibitor; inhibits BMP4 signaling; promotes neural induction of hPSCs
Chemical Name: | 4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline dihydrochloride |
Purity: | ≥98% (HPLC) |
Potent AMPK inhibitor; also BMP type I receptor inhibitor
Alternate Names: | Compound C,BML-275 |
Chemical Name: | 6-[4-[2-(1-Piperidinyl)ethoxy]phenyl]-3-(4-pyridinyl)-pyrazolo[1,5-a]pyrimidine dihydrochloride |
Purity: | ≥98% (HPLC) |
Sterile-filtered 10 mM solution of LDN 193189 pre-dissolved in water
Chemical Name: | 4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline dihydrochloride |
Purity: | ≥97% (HPLC) |
LDN 193189 synthesized to cGMP guidelines
Chemical Name: | 4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline dihydrochloride |
Purity: | ≥99% |
Reactivity: | Human |
Details: | Goat IgG Polyclonal |
Applications: | WB, Flow, CyTOF-ready |
Reactivity: | Human |
Details: | Goat IgG Polyclonal |
Applications: | WB, Flow |
Source: | NS0 |
Accession #: | NP_004320 |
Applications: | BA |
Reactivity: | Human |
Details: | Mouse IgG2b Monoclonal Clone #550607 |
Applications: | IHC |
Reactivity: | Human |
Details: | Mouse IgG1 Monoclonal Clone #4B7B2 |
Applications: | IHC, WB, ELISA, ICC/IF, Flow, +1 More |
Source: | NS0 |
Accession #: | NP_033888 |
Applications: | BA |
Reactivity: | Human |
Details: | Mouse IgG2 Monoclonal Clone #MM0053-8L7 |
Applications: | IHC, WB |
Type I BMP receptor inhibitor
Chemical Name: | 4-[6-[4-[2-(4-Morpholinyl)ethoxy]phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline |
Purity: | ≥98% (HPLC) |
Source: | NS0 |
Accession #: | CAA80257 |
Applications: | BA |
Reactivity: | Human |
Details: | Mouse IgG2a Kappa Monoclonal Clone #4C4 |
Applications: | WB, ELISA |
Applications: | ELISA |
Applications: | ELISA |
Source: | NS0 |
Accession #: | Q60607 |
Applications: | BA |
Reactivity: | Human |
Details: | Goat IgG Polyclonal |
Applications: | WB, ELISA |
Reactivity: | Human |
Details: | Rabbit IgG Polyclonal |
Applications: | WB |
Applications: | ELISA |
Recombinant Monoclonal Antibody
Reactivity: | Mouse |
Details: | Rabbit IgG Monoclonal Clone #002 |
Applications: | ELISA |
Recombinant Monoclonal Antibody
Reactivity: | Mouse |
Details: | Rabbit IgG Monoclonal Clone #002 |
Applications: | ELISA |
Reactivity: | Human |
Details: | Mouse IgG2 Monoclonal Clone #MM0053-8L7 |
Applications: | IHC, WB |